Filing Flows › Supernus Pharmaceuticals (SUPN) › Capital expenditures
Supernus Pharmaceuticals (SUPN) capital expenditures by quarter
Supernus Pharmaceuticals' capital expenditures were $230K in Q3 2026 (third quarter 2026), -46% from Q4 2025. Over the last 4 quarters it ranged from $230K (Q3 2026) to $455K (Q2 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $230K | -46% | — |
| Q4 2025 | $427K | -6% | — |
| Q2 2025 | $455K | +39% | — |
| Q1 2025 | $327K | — | — |
Q3 2026 at a glance
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%, net earnings $20.9M, operating cash flow $6.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Supernus Pharmaceuticals' capital expenditures?
Supernus Pharmaceuticals' capital expenditures were $230K in Q3 2026 (third quarter 2026), -46% from Q4 2025.
How has Supernus Pharmaceuticals' capital expenditures changed?
Over the last 4 quarters it ranged from $230K (Q3 2026) to $455K (Q2 2025).
Q3 2026 results → · How Supernus Pharmaceuticals makes money →